Filing Flows › Anika Therapeutics (ANIK) › Capital expenditures
Anika Therapeutics (ANIK) capital expenditures by quarter
Anika Therapeutics' capital expenditures were $1.7M in Q3 2026 (third quarter 2026), +156% from Q4 2025. Over the last 3 quarters it ranged from $648K (Q4 2025) to $1.9M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.7M | +156% | -12% |
| Q4 2025 | $648K | -66% | — |
| Q3 2025 | $1.9M | — | — |
Q3 2026 at a glance
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Anika Therapeutics' capital expenditures?
Anika Therapeutics' capital expenditures were $1.7M in Q3 2026 (third quarter 2026), +156% from Q4 2025.
How has Anika Therapeutics' capital expenditures changed?
Over the last 3 quarters it ranged from $648K (Q4 2025) to $1.9M (Q3 2025).